NervGen Files Amended 40-F with Restated Financials and Material Weakness Disclosure
NGEN is trading near its 52-week low of $1.55 (2.6% above the low).
Summary
NervGen filed its amended 40-F with restated FY2025 and FY2024 financials, formally disclosing a material weakness in internal controls related to option and warrant valuation. The restatement is non-cash and does not affect cash position or runway.
Key Events · Corporate Governance and Compliance · NGEN
-
Amended 40-F Filed with Restated Financials
Form 40-F/A Amendment No. 1, filed October 16, 2026, contains amended and restated consolidated financial statements for FY2025 and FY2024, along with restated MD&A.
-
Material Weakness in Internal Controls Disclosed
Management identified a material weakness in ICFR: miscalculation of annualized volatility in the Black-Scholes-Merton model used to value options and warrant derivatives, and insufficient segregation of duties in the finance function.
-
Restatement Adjustments Quantified
FY2025 net loss increased by C$97,028 to C$44,214,333; FY2024 net loss decreased by C$585,338 to C$23,664,711. Warrant derivative liability reduced by C$2,419,384 (Dec 2025) and C$3,692,790 (Dec 2024).
-
Restatement is Non-Cash with No Runway Impact
The restatement had no impact on cash, cash equivalents, or net cash used in operating, investing or financing activities for any period presented.
Analysis · NGEN · Life Sciences
NervGen has filed its amended annual report containing the actual restated financial statements for FY2025 and FY2024, formally disclosing a material weakness in internal control over financial reporting. The restatement corrects non-cash valuation errors in stock option and warrant derivative accounting that overstated stock-based compensation expense and warrant derivative liabilities. While the restatement itself is non-cash and does not affect the company's cash position or runway, the formal material weakness disclosure and the need to restate three years of financials raise governance concerns that can weigh on investor confidence. Remediation has begun, with the company hiring an Accounting Manager and Director of Contracts to address segregation of duties deficiencies.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 40% of the 987 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NGEN was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171M. The 52-week trading range was $1.55 to $6.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.